Research Reveals Why People With Type 1 Diabetes May Have Lower Cancer Risk

For years, epidemiologic studies have documented an unusual pattern: people with Type 1 diabetes appear to have lower rates of certain cancers, including melanoma, prostate cancer, and breast cancer. Despite this observation, scientists have not fully understood why. A new study published in the Journal of Immunology offers a potential explanation by examining what happens at the cellular level when immune cells encounter high blood glucose environments.

Researchers used laboratory models of high blood glucose (induced by streptozotocin) alongside tumor models to observe how the body's immune response changed. They found that in high-glucose environments, tumors grew more slowly and mice lived longer. The critical finding: CD8+ T cells—white blood cells that patrol the body for cancer and infection—were significantly more active and effective at killing tumor cells.

Importantly, the tumor cells themselves did not perform differently in high glucose. The advantage lay entirely with the immune system. CD8+ T cells from high-glucose hosts showed greater glycolytic activity (a measure of cellular energy use) and enhanced cytotoxic function—meaning they were better equipped to destroy cancer cells.

The researchers traced the enhanced immune response to a specific signaling pathway: the IGF1R-mTOR axis. This pathway involves two proteins—IGF1 and its receptor (IGF1R)—that help cells sense nutrient availability and regulate growth and metabolism. In high-glucose conditions, CD8+ T cells in tumors showed increased expression of these proteins, as well as increased phospho-mTOR, indicating the pathway was active.

To confirm this pathway's importance, scientists studied CD8+ T cells taken from blood samples of people with high blood glucose and people without diabetes. The high-glucose patient cells displayed superior activation when exposed to tumor antigens in the laboratory. When researchers then blocked IGF1R or mTOR activity, this advantage disappeared, proving the pathway was essential to the effect.

While this research reveals an unexpected silver lining to high blood glucose environments, it does not suggest that elevated glucose is medically beneficial. Instead, the findings point to a cellular mechanism that scientists may be able to activate intentionally through immunotherapy—potentially boosting cancer patients' own immune systems without relying on chronically high blood glucose.

The researchers propose that selectively activating the IGF1R-mTOR signaling pathway in CD8+ T cells could be a promising target for developing more effective cancer immunotherapies. This approach would aim to replicate the enhanced T cell function observed in high-glucose states while avoiding the harms associated with diabetes itself.

This work is foundational research conducted in laboratory and animal models. Further studies will be needed to determine whether these findings can be safely and effectively translated into new treatments for cancer patients. Anyone with questions about their own cancer risk or treatment options should speak with their healthcare provider.

Source: Journal of immunology (Baltimore, Md. : 1950). Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.